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Abstract
Magnesium, potassium, and sodium, cations commonly measured in serum, are involved in many physiological processes
including energy metabolism, nerve and muscle function, signal transduction, and fluid and blood pressure regulation. To
evaluate the contribution of common genetic variation to normal physiologic variation in serum concentrations of these
cations, we conducted genome-wide association studies of serum magnesium, potassium, and sodium concentrations
using ,2.5 million genotyped and imputed common single nucleotide polymorphisms (SNPs) in 15,366 participants of
European descent from the international CHARGE Consortium. Study-specific results were combined using fixed-effects
inverse-variance weighted meta-analysis. SNPs demonstrating genome-wide significant (p,5610
28) or suggestive
associations (p,4610
27) were evaluated for replication in an additional 8,463 subjects of European descent. The
association of common variants at six genomic regions (in or near MUC1, ATP2B1, DCDC5, TRPM6, SHROOM3, and MDS1) with
serum magnesium levels was genome-wide significant when meta-analyzed with the replication dataset. All initially
significant SNPs from the CHARGE Consortium showed nominal association with clinically defined hypomagnesemia, two
showed association with kidney function, two with bone mineral density, and one of these also associated with fasting
glucose levels. Common variants in CNNM2, a magnesium transporter studied only in model systems to date, as well as in
CNNM3 and CNNM4, were also associated with magnesium concentrations in this study. We observed no associations with
serum sodium or potassium levels exceeding p,4610
27. Follow-up studies of newly implicated genomic loci may provide
additional insights into the regulation and homeostasis of human serum magnesium levels.
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Introduction
Magnesium is the secondmostabundant intra-cellularcationand
is a co-factor in several important reactions, including nucleic acid
synthesis and many enzymatic reactions [1]. Nearly 60% of
magnesium in the human body resides in bone, 20% in skeletal
muscle, and 20% in soft tissue. Although only a fraction of total
magnesium is present in blood, serum magnesium concentrations
are reported to associate with severalcommon and chronic diseases,
including diabetes [2], hypertension [3], and osteoporosis [4].
Sodium and potassium are the most abundant cations in extra- and
intracellular fluids, respectively [5], and are also commonly
measured in serum. They have important roles in the maintenance
of fluid and electrolyte balance as well as cell excitability.
Although most magnesium deficiencies are acquired [6], serum
magnesium concentrations have been shown to have a heritable
component with heritability estimates of ,30% [7,8]. In addition,
several rare monogenic disorders have been identified that are
characterized by abnormalities in magnesium homeostasis [1,6,9],
including Gitelman syndrome (OMIM #263800), Bartter syn-
drome (OMIM #601678, #241200, #607364), and several
hypomagnesemia syndromes (OMIM #602014, #154020,
#248250, #611718, and #248190). Heritability estimates for
serum sodium and potassium concentrations were comparable to
the ones for magnesium in previous studies [10–13], and several
monogenic diseases with disturbances in serum potassium or
sodium concentrations exist [14].
Information on common genomic variants that are associated
with serum cation concentrations in the general population may
provide insights into physiologic regulators of electrolyte homeo-
stasis. Thus, we undertook genome-wide association studies
(GWAS) of serum magnesium, potassium and sodium concentra-
tions in 15,366 subjects in the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium.
Since the kidney has an essential role in maintaining serum
concentrations of these cations, and since magnesium, sodium, and
potassium have been implicated in blood pressure regulation, we
also assessed whether our newly identified variants were associated
with glomerular filtration rate (eGFR) estimated from serum
creatinine levels as a measure of kidney function as well as with
systolic and diastolic blood pressure (SBP and DBP) in the
CHARGE Consortium. We further evaluated the identified
variants in association with fasting glucose in the Meta-Analyses
of Glucose and Insulin Related Traits Consortium (MAGIC) [15]
and bone mineral density (BMD) in the Genetic Factors for
Osteoporosis (GEFOS) Consortium [16]; two continuous traits
used to identify the presence of diabetes and osteoporosis.
Results
Overall, 15,366 individuals of European descent from the
Atherosclerosis Risk in Communities (ARIC) Study (N=8,122),
the Framingham Heart Study (FHS; N=2,866), and the
Rotterdam Study (RS; N=4,378) contributed data to the
discovery analyses of common variants associated with serum
magnesium concentrations. Meta-analysis of serum sodium
concentrations included information from 11,552 individuals from
the three cohorts, and 13,683 individuals contributed information
to the meta-analysis of serum potassium concentrations (including
3,370 participants from the Cardiovascular Health Study [CHS]).
Selected characteristics for these four study samples as well as an
additional CHARGE cohort that contributed information to
secondary analyses of kidney function and blood pressure [The
Age, Gene/Environment Susceptibility (AGES) —Reykjavik
Study (N=3,219)] are reported in Table 1.
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(SNPs) were examined in association with serum magnesium,
sodium, and potassium within each study, and the findings were
meta-analyzed across studies using inverse-variance weighted
fixed-effects models. SNPs were imputed in the individual studies
as described in Table S1. No genome-wide significant
(p,5610
28) or suggestive (p,4610
27) results were observed for
serum sodium or potassium concentrations after adjustment for
age, sex, and study center (where applicable). SNPs that showed
evidence for association at p,1610
25 after correction for
genomic control are provided in Table S2 (sodium) and Table
S3 (potassium). Q-Q plots of the observed versus expected p-value
distributions for associations between the ,2.5 million SNPs and
magnesium, sodium and potassium levels are provided in Figure
S1A, S1B, S1C. Heritability of serum magnesium, sodium, and
potassium was estimated in the family-based FHS. Heritability was
significant for serum magnesium (0.45; SE=0.06; p=1610
213,
N=2,657) but not for serum sodium (0.04; SE=0.06; p=0.27,
N=2,416) or potassium (0.03; SE=0.06; p=0.29, N=2,418)
after excluding individuals on hypertension treatment. The traits
were only weakly correlated in the ARIC study, the largest cohort
in CHARGE (r
2#0.15).
Figure 1 shows the Manhattan plot for associations between
SNPs and magnesium levels in the discovery cohorts after
adjustment for age, sex, and center (where applicable). There
were six regions with variants associated with serum magnesium
concentrations at a genome-wide significance level of p,5610
28.
Information about the SNP with the lowest p-value within each
region (lead SNP) is presented in Table 2; the lead SNPs were
located in or near MUC1 (91 kb region, chr 1), SHROOM3 (175 kb
region, chr 4), TRPM6 (77 kb region, chr 9), DCDC5 (25 kb
region, chr 11), ATP2B1 (233 kb region, chr 12), and PRMT7
(395 kb region, chr 16). Individually, the six genome-wide
significant SNPs in the combined discovery and replication
cohorts explained between 0.1 and 0.6% of the variance in serum
magnesium concentrations; jointly, they explained about 1.6% of
the variance (1.9% in the discovery cohorts and 1.2% in the
replication cohorts). Three additional regions showed evidence of
suggestive association (p,4610
27) with serum magnesium
concentrations (Table 2). Associations between the lead SNPs
and serum magnesium within each of the discovery cohorts as well
as their combined effect are presented in Table S4. Summary
information for all SNPs associated with serum magnesium at
p,10
26 is included in Table S5. Regional association plots for the
six genomic regions with evidence for genome-wide association in
the discovery cohorts are provided in Figure S2A, S2B, S2C, S2D,
Table 1. Baseline characteristics of the CHARGE Consortium discovery cohorts.*
ARIC (N=8,122) FHS (N=2,866) RS (N=4,378) AGES (N=3,219) CHS (N=3,370)
N( % )
Men 3,831 (47) 1,372 (48) 1,690 (39) 1,352 (42) 1,339 (40)
Hypertension 2,201 (27) 575 (20) 2,478 (57) 1,127 (35) 1,533 (45)
Using hypertension medications 2,076 (26) 247 (9) 1,447 (26) 208 (6) 1,201 (36)
Hypomagnesemia (,0.7 mmol/L) 638 (8) 22 (1) 411 (9) NA NA
Mean6SD
Age (y) 5465.7 4369.8 7069.0 5166.4
{ 7265.4
BMI (kg/m
2)2 7 64.9 2564.0 2663.7 2563.5 2664.5
eGFR (ml/min/1.73 m
2)9 0 617.9 103636.1 71617.2 72620.0
{ 80622.6
SBP (mmHg) 119617.0 121616.0 139622.1 132616.9 135621.0
DBP (mmHg) 72610.0 7869.6 74611.7 8369.6 70611.4
Magnesium (mmol/L) 0.8360.07 0.9460.08 0.8160.09 NA NA
AGES, Age, Gene/Environment Susceptibility—Reykjavik Study; ARIC, The Atherosclerosis Risk in Communities Study; BMI, body mass index; CHARGE, Cohorts for Heart
and Aging Research in Genomic Epidemiology; CHS, The Cardiovascular Health Study; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FHS, The
Framingham Heart Study; NA, not available; RS, The Rotterdam Study; SBP, systolic blood pressure; SD, standard deviation.
*Characteristics are reported for the population with magnesium concentrations for ARIC, FHS, and RS and for the population with information on blood pressure for
CHS and AGES.
{Age reported is at the time of blood pressure measurement. eGFR was measured at an average age of 75.
doi:10.1371/journal.pgen.1001045.t001
Author Summary
Magnesium, potassium, and sodium are involved in
important physiological processes. To better understand
how common genetic variation may contribute to inter-
individual differences in serum concentrations of these
electrolytes, we evaluated single nucleotide polymor-
phisms (SNPs) across the genome in association with
serum magnesium, potassium, and sodium levels in 15,366
participants of European descent from the CHARGE
Consortium. We then verified the associations in an
additional 8,463 study participants. Six different genomic
regions contain variants that are reproducibly associated
with serum magnesium levels, and only one of the regions
had been previously known to influence serum magne-
sium concentrations in humans. The identified SNPs also
show association with clinically defined hypomagnesemia,
and some of them with traits that have been linked to
serum magnesium levels, including kidney function,
fasting glucose, and bone mineral density. We further
provide evidence for a physiological role of magnesium
transporters in humans which have previously only been
studied in model systems. None of the SNPs evaluated in
our study are significantly associated with serum levels of
sodium or potassium. Additional studies are needed to
investigate the underlying molecular mechanisms in order
to help us understand the contribution of these newly
identified regions to magnesium homeostasis.
Genome-Wide Association Study of Serum Magnesium
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medications were excluded from the discovery analysis.
Replication of the lead SNPs with evidence of significant or
suggestive association in the discovery cohorts was attempted in an
additional 8,463 independent individuals of European descent
(N=1,641, KORA F3 Study; N=1,809, KORA F4 Study;
N=4,065, SHIP Study; N=948, ARIC Study). Mean serum
magnesium levels in the replication cohorts were 0.8360.07
(ARIC), 0.8660.07 (KORA F3), 0.9160.06 (KORA F4), and
0.7860.09 (SHIP) mmol/L. At a Bonferroni-corrected signifi-
cance level of 5.5610
23 (0.05/9), five of the six SNPs with
evidence of genome-wide significant association in the discovery
samples showed evidence for replication in the independent
replication cohorts (Table 2). Of the three SNPs with suggestive
evidence for association in the discovery cohorts, the SNP at the
MDS1 locus showed evidence for independent replication, and
combined with the discovery samples, reached a genome-wide
level of significance (Table 2). Cohort-specific associations for the
replication cohorts along with summary associations are presented
in Table S6. Information about the quality of imputation for the
lead SNPs within each cohort is reported in Table S7.
Replicated SNPs with evidence for genome-wide association in
the discovery cohorts were related to clinically relevant hypomag-
nesemia, using a 0.7 mmol/L cutpoint [17]. All SNPs showed
Figure 1. Genome-wide –log10(p-value) plot from association analyses with serum magnesium concentrations in 15,366
participants of European ancestry from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium. Adjusted for age, sex, and center.
doi:10.1371/journal.pgen.1001045.g001
Table 2. Associations between serum magnesium levels and the lead regional genome-wide significant SNPs in the combined
discovery (N=15,366) and replication (N=8,463) samples.
SNP CHR
Location (base
pairs)
* Function CAF
Coded/
Other
Allele
{
Closest
Gene
% Variance
Explained
Beta
(mmol/L)
{ SE P
SNPs with genome-wide significant association after discovery (p,5610
28)
rs4072037 1 155162067 synonymous 0.46 C/T MUC1 0.57 20.010 0.001 2.01E-36
rs13146355 4 77412140 Intronic 0.56 G/A SHROOM3 0.19 20.005 0.001 6.27E-13
rs11144134 9 77499796 Intronic 0.92 T/C TRPM6 0.23 20.011 0.001 8.21E-15
rs3925584 11 30760335 Intergenic 0.45 C/T DCDC51 0.25 20.006 0.001 5.20E-16
rs7965584 12 90305779 Intergenic 0.29 G/A ATP2B11 0.25 20.007 0.001 1.05E-16
rs7197653 16 68383047 Intronic 0.15 C/G PRMT7 0.10 20.005 0.001 2.02E-06
SNPs with suggestive association after discovery (p,4610
27)
rs2592394 2 176991779 Intergenic 0.30 A/G HOXD91 0.09 20.004 0.001 4.61E-07
rs448378 3 169100899 Intronic 0.47 G/A MDS1 0.13 20.004 0.001 1.25E-08
rs4561213 11 24678819 Intronic 0.53 G/T LUZP2 0.09 20.004 0.001 2.60E-07
CHR, chromosome; CAF, coded allele frequency; SE, standard error; SNP, single nucleotide polymorphism.
*Location and distance to closest gene based on provisional NCBI Build 37.1.
{Coded alleles are inversely associated with magnesium.
{Adjusted for age, sex, and study center (if applicable).
1SNPs are located near the gene: rs3925584 is 126,151 bp from DCDC5, rs7965584 is 1,151,916 bp from ATP2B1and rs2592394 is 2,255 bp from HOXD9.
doi:10.1371/journal.pgen.1001045.t002
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1.11 (SHROOM3) to 1.27 (MUC1) per copy of the magnesium-
lowering allele (Table 3).
As the kidney is one of the primary regulators of serum
magnesium concentrations, we also examined these SNPs in
association with the kidney function measure, eGFR. The allele
associated with lower magnesium levels at two of the SNPs showed
evidence for association with higher eGFR: rs3925584 near
DCDC5 (p=4.1610
25) and rs77412140 in SHROOM3 (p=
4.3610
211; Table 3). Adjusting the magnesium-SNP associations
for eGFR did not materially change the association with serum
magnesium levels (eGFR-adjusted beta=20.006, p=6.3610
212
for the DCDC5 and beta=20.005, p=9.5610
29 for the
SHROOM3 SNP).
Since magnesium levels associate with hypertension [3],
diabetes [2], and osteoporosis [4] in observational studies, we
further evaluated the lead replicated SNPs in association with the
continuous traits used to define these chronic conditions: SBP and
DBP (CHARGE cohorts), fasting glucose (MAGIC Consortium
[15]) and BMD (GEFOS Consortium [16]). None of the SNPs was
associated with SBP or DBP in our study (Table S8), but the allele
associated with lower magnesium levels at the MUC1 SNP showed
nominally-significant evidence of association with lower fasting
glucose after correcting for the number of SNPs investigated
(Bonferroni-corrected significance level=0.05/5=0.01; Table 3).
The same allele showed association with higher BMD, as did the
magnesium-lowering allele of the TRPM6 SNP (Table 3).
Finally, in the CHARGE discovery cohorts, we evaluated genes
that contain rare variants known to cause monogenic syndromes of
abnormal magnesium metabolism [6] for common susceptibility
variants that associate with normal magnesium levels. We also
evaluated common SNPs in genes that have been implicated as
magnesium transporters in model systems [18] but, to date, have
an unknown functional role in humans from the general
population. The number of SNPs per gene examined as well as
summary information for the SNP with the lowest p-value from
Table 3. Association between hypomagnesemia, estimated glomerular filtration rate, fasting glucose, and bone mineral density
with the lead replicated SNPs showing genome-wide significant associations with serum magnesium concentrations.
SNP CHR Closest Gene N Allele OR
* 95% CI P
Hypomagnesemia
{
rs4072037 1 MUC1 12,500 C 1.27 1.16–1.39 3.92E-07
rs13146355 4 SHROOM3 12,500 G 1.11 1.01–1.21 3.30E-02
rs11144134 9 TRPM6 12,500 T 1.20 1.00–1.44 4.57E-02
rs3925584 11 DCDC5 12,500 C 1.18 1.08–1.29 3.22E-04
rs7965584 12 ATP2B1 12,500 G 1.24 1.13–1.37 6.38E-06
SNP CHR Closest Gene N Beta
* SE P
Estimated glomerular filtration rate (eGFR)
{
rs4072037 1 MUC1 21,805 C 1.31E-04 0.002 9.54E-01
rs13146355 4 SHROOM3 21,805 G 0.015 0.002 4.28E-11
rs11144134 9 TRPM6 21,805 T 21.79E-04 0.004 9.68E-01
rs3925584 11 DCDC5 21,805 C 0.009 0.002 4.11E-05
rs7965584 12 ATP2B1 21,805 G 0.004 0.002 1.32E-01
Fasting glucose
1
rs4072037 1 MUC1 40,496 C 20.012 0.004 3.58E-03
rs13146355 4 SHROOM3 45,727 G 3.00E-04 0.004 9.33E-01
rs11144134 9 TRPM6 28,137 T 0.006 0.010 5.30E-01
rs3925584 11 DCDC5 46,180 C 20.001 0.004 8.89E-01
rs7965584 12 ATP2B1 46,171 G 0.002 0.004 6.69E-01
Femoral Neck bone mineral density (BMD)
I
rs4072037 1 MUC1 19,195 C 0.039 0.012 1.17E-03
rs13146355 4 SHROOM3 19,195 G 0.008 0.012 4.92E-01
rs11144134 9 TRPM6 19,195 T 0.076 0.025 2.00E-03
rs3925584 11 DCDC5 19,195 C 20.006 0.012 5.84E-01
rs7965584 12 ATP2B1 19,195 G 20.007 0.013 5.80E-01
CHR, chromosome; CI, confidence interval; OR, odds ratio; SE, standard error; SNP, single nucleotide polymorphism.
*Adjusted for age, sex, and study center (if applicable); the association reported is for the magnesium-lowering allele.
{Includes the following CHARGE cohorts: ARIC (N=8,122), RS (N=4,378); OR is from logistic regression of hypomagnesemia (,0.7 mmol/L).
{Includes the following CHARGE cohorts: AGES (N=3,219), ARIC (N=8,069), CHS (N=3,282), FHS (N=2,861), RS (N=4,374); beta is for natural log transformed eGFR (ml/
min/1.73 m
2).
1Results are from meta-analyses of up to 46,180 individuals from 21 MAGIC cohorts in non-diabetics of European ancestry; beta is for each unit increase in fasting
glucose (mmol/L) and is additionally adjusted for geographic covariates (where applicable) and age squared (FHS only).
IResults are from meta-analyses of 19,195 individuals from five cohorts in the GEFOS consortium; beta is for per allele-copy change of BMD as measured in standard
deviations from the population mean and is adjusted for age, weight, sex, and study. Associations with lumbar spine BMD were similar to femoral neck BMD.
doi:10.1371/journal.pgen.1001045.t003
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(rs3740393, p=8.6610
27), CNNM3 (rs994430, p=1.5610
24) and
CNNM4 (rs6746896, p=7.0610
25) were associated with magne-
sium concentrations after applying a Bonferroni-correction for the
number of SNPs examined in each region.
Discussion
We report a large genome-wide association study of serum
magnesium, potassium and sodium levels in 15,366 community-
dwelling subjects of European ancestry from the CHARGE
Consortium. Associations with serum potassium and sodium did
not reach the level of genome-wide significance in our study, but
common genetic variants in six genomic regions in or near the
MUC1, MDS1, SHROOM3, TRPM6, DCDC5, and ATP2B1 genes
were significantly and reproducibly associated with serum
magnesium levels and clinically defined hypomagnesemia. To-
gether, these SNPs explained about 1.6% of variation in serum
magnesium levels. Variation at the DCDC5 SNP (rs3925584) on
chromosome 11 and the SHROOM3 SNP (rs13146355) on
chromosome 4 was also independently associated with eGFR, a
measure of kidney function, while the MUC1 SNP (rs4072037) was
associated with fasting glucose as well as BMD and the TRPM6
(rs11144134) SNP was associated with BMD. Finally, we provide
evidence for a role of the magnesium transporters encoded by
CNNM2 as well as CNNM3 and CNNM4 in the regulation of
physiological magnesium homeostasis in humans.
Magnesium homeostasis is maintained as a balance between
intestinal magnesium absorption and renal magnesium excretion
[7]. Magnesium transport in the kidney occurs both by passive
paracellular reabsorption in the loop of Henle and by active
transcellular reabsorption in the distal convoluted tubule [7].
Of the loci discovered here, only TRPM6 on chromosome 9 had
a previously known role in magnesium homeostasis. TRPM6
Table 4. SNPs in or near genes known to cause monogenic syndromes with abnormal magnesium metabolism or near known
magnesium transport genes in association with serum magnesium in 15,366 participants from the CHARGE Consortium.
Gene # of SNPs
{ Lead SNP CAF
Coded/
Other Allele CHR
Location (base
pairs)
Beta
(mmol/L)
{ SE P
Mendelian Genes
CLCNKB 108 rs848305 0.89 T/A 1 16316825 20.007 0.002 2.74E-03
CLDN19 62 rs719676 0.76 A/G 1 43254108 20.002 0.001 5.51E-02
BSND 174 rs9326034 0.01 A/G 1 55530664 20.018 0.006 5.18E-03
CASR 261 rs17251221 0.86 A/G 3 121993247 20.004 0.001 1.31E-03
CLDN16 213 rs9990270 0.42 C/G 3 190176606 20.002 9.00E-04 2.58E-02
EGF 255 rs11569033 0.96 A/G 4 110905803 20.013 0.004 1.39E-03
FXYD2 165 rs948100 0.09 G/A 11 117660275 20.003 0.002 3.65E-02
KCNJ1 190 rs496844 0.49 G/C 11 128650029 20.002 9.00E-04 2.49E-03
SLC12A1 100 rs17428448 0.01 G/T 15 48551594 20.049 0.022 2.62E-02
SLC12A3 195 rs8048695 0.02 A/G 16 56910986 20.023 0.007 7.64E-04
Magnesium Transport Genes
1
SLC41A1 117 rs17348507 0.05 G/A 1 205814735 20.004 0.002 5.39E-02
CNNM4 42 rs6746896 0.66 A/G 2 97410949 20.004 0.001 7.01E-05
CNNM3 46 rs994430 0.59 A/T 2 97439001 20.004 9.00E-04 1.53E-04
SLC41A3 277 rs7617162 0.35 T/C 3 125755450 20.002 9.00E-04 2.03E-02
NIPAL1 (NPAL1) 100 rs17470528 0.83 T/C 4 48052003 20.003 0.001 1.73E-02
NIPAL4 (ICHTHYIN) 124 rs11134799 0.11 C/T 5 156958290 20.003 0.001 5.68E-02
BTBD9 536 rs4714146 0.91 G/A 6 38287910 20.006 0.002 5.00E-04
ZDHHC13 228 rs7116312 0.27 G/A 7 19079292 20.004 0.001 5.31E-04
TUSC3 557 rs12681567 0.10 A/C 8 15657603 20.003 0.002 2.35E-02
CNNM1 211 rs2490281 0.97 G/C 10 101192482 20.006 0.003 3.92E-02
CNNM2 222 rs3740393 0.86 G/C 10 104636655 20.006 0.001 8.58E-07
ZDHHC17 170 rs11115332 0.96 C/G 12 77171192 20.004 0.002 8.65E-02
SLC41A2 197 rs2463021 0.88 A/T 12 105168431 20.003 0.002 3.99E-02
NIPA1 123 rs4778439 0.95 G/A 15 23002053 20.005 0.002 3.23E-02
NIPA2 147 rs4778439 0.95 G/A 15 23002053 20.005 0.002 3.23E-02
TRPM7 177 rs2163098 0.03 G/C 15 50906498 20.005 0.003 6.01E-02
CAF, coded allele frequency; SE, standard error; SNPs, single nucleotide polymorphisms.
SNP locations are based on the provisional NCBI Build 37.1.
{Within 60 kb of the gene.
{Adjusted for age, sex, and study center (if applicable); the association reported is for the magnesium-lowering allele and p-values are adjusted for genomic control.
Proportion of variance in serum magnesium levels explained by the listed SNPs ranged from 0.11% by rs17251221 to ,0.001.
1MAGT1 and MMGT1were not investigated because of their localization on the X chromosome.
doi:10.1371/journal.pgen.1001045.t004
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expressed in the gut and the kidney [19,20], where it is responsible
for transcellular magnesium transport by mediating magnesium
reuptake at the apical membrane of renal epithelial cells in the
distal tubule [9]. Rare mutations in TRPM6 are a cause of
autosomal recessive hypomagnesemia with secondary hypocalce-
mia (OMIM #602014) [19,20]. The common T allele of
rs11144134 in TRPM6 that associated with lower serum
magnesium levels in our study was also associated with higher
femoral neck and lumbar spine BMD. Although magnesium-
deficiency has been linked to osteoporosis and low BMD in
observational and animal studies [9], our observations are in line
with the higher BMD observed in patients with low plasma
magnesium levels as a result of Gitelman’s syndrome [21].
On chromosome 12, we identified variants in the ATP2B1 gene
region as associated with serum magnesium concentrations. This
gene encodes plasma-membrane calcium ATPase 1 (PMCA1)
[22], responsible for the removal of calcium ions from cells. One
previous study reported that the phosphatase activity of PMCA1 is
dependent on magnesium ions [23]. While magnesium uptake via
TRPM6 at the apical membrane of epithelial cells has been
demonstrated as the mechanism for magnesium entry, the
mechanism by which magnesium ions exit the cells at the
basolateral membrane is hitherto unknown [9]. Our epidemiologic
findings relating variation in ATP2B1 to serum magnesium
concentrations, combined with the localization of PMCA1 in the
basolateral membrane of epithelial cells in the distal renal tubule,
makes PMCA1 an interesting candidate for further functional
studies of renal magnesium transport. The genomic region
containing the ATP2B1 gene was previously identified in a
genome-wide association study of blood pressure and hypertension
[24]. Linkage disequilibrium (LD) between the blood pressure
associated variant and the one reported in our study is low
(r
2=0.013 in HapMap CEU), supporting the independent effects
of the two variants on blood pressure and magnesium homeostasis.
The genomic region containing the SHROOM3 gene on
chromosome 4 has been associated with eGFR in a previous
GWAS [25] and with serum creatinine in another large
consortium study [26]. Previously described eGFR/creatinine-
associated variants are in strong LD with the magnesium-
associated one reported in our study (r
2.0.8 in HapMap CEU),
in agreement with the significant association with eGFR detected
in our study (p=4.3610
211). The magnitude of the association
between the SNP and magnesium levels remained unchanged
after adjustment for eGFR, which may suggest a pleiotropic effect
of the same underlying causal variant.
The region on chromosome 1 spans about 100 kb and contains
many genes. The SNP with the strongest association within this
region was located in the gene MUC1. MUC1 encodes mucin 1, a
membrane bound, glycosylated phosphoprotein. It is attached to
the apical surface of many epithelia, where it binds pathogens and
functions in a cell signaling capacity. Aberrant forms of the protein
have been associated with carcinomas. In addition to the observed
association with lower serum magnesium levels, the C allele at
rs4072037 in MUC1 was also associated with higher femoral neck
and lumbar spine BMD as well as with lower fasting glucose levels
in two large consortia. The direction of association with BMD is
consistent with the one we observed for the magnesium-lowering
allele of rs11144134 in TRPM6.
The closest gene to the associated SNP on chromosome 11,
rs3925584, is doublecortin domain containing 5 (DCDC5)o f
currently unknown physiological function. LD in the region also
extends to the neighboring MPPED2 gene, which encodes for a
metallophosphoesterase that needs divalent metal ions for its
catalytic activity [27]. Variants in the DCDC5 genetic region were
identified in a large GWAS as associated with lumbar spine BMD
[16]. Although the reported BMD-associated variant and the
variant associated with serum magnesium in our study are only in
low LD (r
2=0.04 in HapMap CEU), it is of interest that variation
in three regions identified in our study (MUC1, TRPM6, DCDC5)
can be linked to measures of BMD. In addition, the SNP we
identified near DCDC5 also showed some association with eGFR,
and the association with magnesium levels remained unchanged
upon adjustment for eGFR.
Finally, the rs448378 SNP on chromosome 3 is located in the
myelodysplasia syndrome 1 (MDS1) gene. Like MUC1 and
DCDC5, MDS1 is not an obvious candidate for magnesium
homeostasis based on prior biological knowledge.
Previous studies in model systems have identified several genes
coding for magnesium transport proteins [7,28–34], but the
contribution of common genetic variation in these genes to
magnesium homeostasis in humans is unclear. Common variants
in CNNM2, CNNM3, and CNNM4 showed significant association
with serum magnesium concentrations in our study after applying
a conservative Bonferroni correction for the number of regional
SNPs investigated, supporting the role of these proteins in human
magnesium homeostasis under physiological conditions. The
CNNM2-encoded magnesium transporter, ACDP2, belongs to
the ancient conserved domain proteins (ACDP) family [35]. It is
widely expressed in human tissues with strongest levels in brain,
kidney and placenta [35], and experimental studies provide
evidence for its involvement in magnesium transport [29,36]. Rare
mutations in CNNM4 have recently been reported as a cause of
autosomal-recessive cone-rod dystrophy with amelogenesis im-
perfecta [37,38]. A magnesium transport function of the encoded
ACDP4 has not yet been shown. Little is known about ACDP3
encoded by CNNM3; due to the close physical proximity of
CNNM3 and CNNM4, common variants associated with magne-
sium concentrations in our study may not represent independent
signals. We further identify several common variants in genes
responsible for monogenic disorders of magnesium metabolism
that show some degree of association with serum magnesium
concentrations in our study. As true associations may be missed at
the stringent significance levels applied in genome-wide association
studies, we noted the SNP with the lowest p-value in each of the
genetic regions although they did not show evidence of genome-
wide significant association. These results should therefore be
interpreted with caution; on the other hand, applying a region-
wide Bonferroni-correction as we did for these candidate regions
may be overly conservative due to the presence of linkage
disequilibrium.
There are several potential explanations for the observed lack of
genome-wide evidence of associations with serum potassium or
sodium levels in our study. While we had based our decision to
conduct GWAS of serum sodium and potassium levels on earlier
point estimates for heritability on the order of 25–30%, we only
observed significant heritability for serum magnesium levels but
not for serum levels of sodium or potassium. These findings are not
necessarily inconsistent with previous estimates since earlier studies
were mostly small and the 95% confidence intervals of heritability
estimates for either serum sodium or potassium concentrations or
both included 0. Other potential explanations for the difference in
heritability estimates include our exclusion of individuals on
hypertension medication, differences in the statistical model, and
differences in study sample characteristics. Another reason for the
lack of findings could be that genetic variants other than common
SNPs could be of importance, which could not be detected in our
study. Finally, fewer individuals were available for the analyses of
Genome-Wide Association Study of Serum Magnesium
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magnesium concentrations thus impacting statistical power. The
weak correlation of serum magnesium with serum sodium and
potassium levels we observed (r
2#0.15) is consistent with the
identification of genomic regions specific to serum magnesium.
Several limitations of this study should be considered when
interpreting the results. Serum magnesium concentrations repre-
sent only a small portion of the total magnesium stores in the body,
and markers associated with serum magnesium concentrations are
therefore not necessarily markers of total magnesium stores.
Second, results from our study are based on individuals of
European descent only and should be replicated in other
ethnicities. Third, our study likely did not have sufficient power
to detect common variants in association with serum sodium or
potassium concentrations. Finally, the functional significance of
the lead SNPs identified in this study is unknown, and true causal
variants likely remain to be determined. The proportion of serum
magnesium variance explained by the SNPs identified here is
modest, as has been observed from GWAS of other traits [39].
However, the genes discovered in our study provide a basis for
future studies of magnesium homeostasis and for the targeted
investigation of the presence of rare genetic variants of larger
effect.
In conclusion, we identified six genomic regions that contained
common variants reproducibly associated with serum magnesium
levels in a genome-wide meta-analysis of CHARGE cohorts and
four independent replication cohorts. All of the variants were
nominally associated with clinically defined hypomagnesemia, and
lead SNPs in four of the regions were also associated with
measures of kidney function, fasting glucose, and BMD. As only
the TRPM6 gene was previously known to be involved in
magnesium homeostasis, follow-up of the other associated regions
may provide additional clues to the regulation of magnesium
homeostasis in humans.
Materials and Methods
Ethics statement
Each of the cohorts collected written informed consent from
study participants and received approval from their respective
Institutional Review Boards.
Discovery study samples
The CHARGE Consortium was established to facilitate meta-
analysis of GWAS for traits related to cardiovascular disease
(CVD) and aging [40]. Briefly, five large, population-based cohort
studies from the United States and Europe with genome-wide
genotyping information available in 2007 to 2008 were included:
AGES—Reykjavik, ARIC, CHS, FHS, and RS. Detailed
information about each cohort is provided in other references
(AGES—Reykjavik [41]; ARIC [42]; CHS [43]; FHS [44–47]; RS
[48]) and is summarized below.
The AGES—Reykjavik Study includes a sample of 5,764
survivors from the Reykjavik Study of 30,795 men and women
born between 1907 and 1935. The ARIC study includes 15,792
men and women aged 45 to 64 who were enrolled in a prospective
follow-up study from four US communities from 1987 to 1989.
The CHS includes 5,201 mostly Caucasian participants aged 65
years or older that were randomly sampled from Medicare lists in
four US communities from 1989 to 1990. The FHS recruited
5,209 participants aged 28 to 62 from Framingham, Massachusetts
beginning in 1948. Beginning in 1971, 5,124 offspring of the
original cohort members and the offspring’s spouses were also
recruited as part of the Offspring Cohort. FHS subjects in this
study are from the Offspring Cohort who attended the second
examination in 1971–1973. Finally, the RS recruited 7,983
subjects aged 55 years or older from Ommoord, a suburb of
Rotterdam, between 1990 and 1993. Only subjects self-reporting
European ancestry from each cohort are included as a part of this
study.
Replication study samples
ARIC Study. After conducting the meta-analysis within the
CHARGE Study, genotype data on an additional 948 study
participants of European ancestry became available within ARIC.
These individuals were independent from the ones included in the
discovery sample: they were not part of the discovery, had no first-
degree relationship with any individual in the discovery sample,
and would not have been classified as an outlier based on allele
sharing measures generated during quality control procedures of
the discovery sample.
KORAF3andF4. The KORA Studyis a seriesofindependent
population-based epidemiological surveys of participants living in
the region of Augsburg, Southern Germany [49]. All survey
participantswereresidents ofGerman nationalityidentified through
the registration office and were examined in 1994/95 (KORA S3)
and 1999/2001 (KORA S4). In 2004/05, 3,006 subjects
participated in a 10-year follow-up examination of S3 (KORA
F3) and in 2006/08, 3,080 subjects participated in a 7-year follow-
up examination of S4 (KORA F4). Individuals for genotyping in
KORA F3 and KORA F4 were randomly selected. The age range
of the participants was 25 to 74 years at recruitment.
SHIP. The Study of Health in Pomerania (SHIP) is a cross-
sectional survey in West Pomerania, the north-east area of
Germany [50]. A sample from the population aged 20 to 79
years was drawn from population registries. Only individuals with
German citizenship and main residency in the study area were
included. Of 7,008 subjects sampled, 4,310 participants comprised
the final SHIP population.
Genotyping and imputation
Details of genotyping methods, exclusion criteria, and imputa-
tion methods for the discovery and replication samples can be
found in Table S1. Briefly, SNPs were genotyped within each
cohort from 2006–2008 using commercially available whole-
genome platforms, and each cohort imputed genotypes to a
common set of about 2.5 million autosomal SNPs. Imputation was
carried out using MACH version 1.09/.15/.16 (AGES—Reykja-
vik, ARIC, FHS, KORA and RS) (accessed from http://www.sph.
umich.edu/csg/abecasis/MACH/), BimBam version 0.99 [51]
software (CHS), or IMPUTEv0.5.0 [52] (SHIP). For the
imputation, genotype data from the individual studies was
combined with genotype data from HapMap CEU samples to
probabilistically infer the allelic dosage for each SNP (a fractional
value from 0.0 to 2.0) based on the HapMap CEU haplotype
structure. Imputation quality scores were calculated for each SNP
as the ratio of observed dosage-variance to the expected binomial
variance.
Study variables
The primary outcomes for this study were serum concentrations
of magnesium, potassium and sodium. We additionally evaluated
the lead SNPs identified in association with other clinically-
relevant phenotypes, including hypomagnesemia (defined as
serum magnesium ,0.7 mmol/L; CHARGE), blood pressure
(CHARGE), eGFR (CHARGE) fasting glucose (MAGIC), and
BMD (GEFOS). Serum magnesium (discovery: ARIC, FHS, RS;
replication: ARIC, KORA F3, KORA F4, SHIP), sodium (ARIC,
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were measured using standard protocols from fasting blood, where
possible. Serum magnesium levels were determined using the
method described by Gindler and Heth with metallochromic dye,
Calmigate [1,-[1-hydroxy-4-methyl-2-phenylazo)-2-napthol-4-sul-
fonic acid] in the ARIC Study, by METPATH in FHS, with a
Merck Diagnostica kit (method Xylidyl blue) on an Elan
Autoanalyzer (Merk) in RS, with a Xylidylblue kit on a Modular
analyzer (Roche) in the KORA Study, or using a commercial
colorimetric test (Roche Diagnostics, Mannheim, Germany) with a
Hitachi 717 autoanalyzer in the SHIP Study. Sodium and
potassium levels were measured using standard ion electrode
devices in all cohorts.
Detailed descriptions of blood pressure and eGFR traits are
given in other references [24,25] and are described in brief here.
Serum creatinine, used to calculate eGFR, was measured using a
modified kinetic Jaffe method (ARIC, CHS, FHS, RS) or an
enzymatic method (AGES—Reykjavik). Creatinine values were
calibrated to age- and sex-adjusted mean values from a nationally
representative study as described previously [53], and eGFR (ml/
min/1.73 m
2) was calculated using the 4-variable MDRD Study
formula [54]. Due to the skewed distribution, a natural log
transformation was applied before the association analyses.
Repeated resting SBP and DBP measures were recorded by
trained staff in all studies, and the average of multiple readings was
used. Height and weight were measured by trained study
personnel in all studies and were used to calculate BMI (kg/m
2).
Use of blood pressure medications was defined differently in the
different cohorts, but for all cohorts, hypertension medication use
was determined at the time of serum electrolyte determination and
included all classes of anti-hypertension medications commonly
prescribed at the time, including beta-blockers, diuretics, ACE-
inhibitors, angiotensin type-2 antagonists, calcium-channel block-
ers, as well as combination therapies.
Statistical analysis
SNPs were modeled as allelic dosages in all analyses. Genome-
wide analyses of electrolyte concentrations (magnesium, potassi-
um, and sodium) were conducted within the R package
ProbABEL (http://mga.bionet.nsc.ru/,yurii/ABEL/) [55] for
ARIC, CHS and RS, or using linear mixed effects regression
models in the R kinship package to account for pedigree structure
in FHS. SNP-electrolyte associations were adjusted for age, sex,
and study center, where applicable. For analyses of sodium and
potassium concentrations subjects using any hypertension medi-
cations at the time of electrolyte assessment were excluded to avoid
a possible influence of the medications on serum concentrations of
sodium and potassium. Genomic control correction based on
median chi-square was used within each study to adjust for
inflation of the test statistics prior to meta-analysis, as well as
applied to the combined results after the meta-analysis. Inverse-
variance weighted fixed-effects meta-analyses were carried out by
two independent analysts using the software METAL (www.sph.
umich.edu/csg/abecasis/metal/) for the ,2.5 million SNPs across
ARIC, FHS, RS, and CHS (potassium only). After meta-analysis,
results were filtered to remove SNPs with low minor allele
frequency (,0.01). Statistical heterogeneity was evaluated using
Cochrane’s x
2 test (Q-test). P-values ,5610
28 were used to
indicate genome-wide significant results. The size of the associated
regions was determined using the positions of the most upstream
and downstream regional SNPs with p-values,5610
25. Manhat-
tan and Q-Q plots were generated for the meta-analyzed data
using the R statistical software package (http://www.R-project.
org). Plots of the –log10(p-values) by genomic position for
associations within regions of statistical significance were generat-
ed using the SNAP program (http://www.broad.mit.edu/mpg/
snap/ldsearch.php). In SNAP, the HapMap CEU population was
used as the reference group to map LD patterns. In the family-
based FHS, heritability of serum magnesium, sodium, and
potassium was estimated using age and sex-adjusted residuals in
a variance components model that estimated additive genetic
heritability and a random environmental component using
SOLAR v.1.4 [56].
The six lead SNPs with evidence of genome-wide significant
association in discovery plus an additional three SNPs with
suggestive evidence of association were evaluated for independent
replication. In the replication studies, SNP-magnesium associa-
tions were determined in linear regression models as described for
the discovery cohorts. Inverse-variance weighted fixed effects
meta-analysis was used to determine associations across the
replication samples and to calculate the overall combined
associations for the discovery and replication cohorts.
For the lead SNPs, we calculated the percent of magnesium
variance attributable to the SNP as the difference in the adjusted
r
2 value for a model containing the SNP, age, sex, and study
center, where applicable, to a model containing only age, sex and
study center, expressed as a percent. Assuming independent effects
of the SNPs, we added the individual variance across the SNPs to
calculate the total variance explained by the set of SNPs. The
independence assumption was verified by simultaneous inclusion
of all SNPs into a regression model. We also evaluated the five lead
SNPs from CHARGE with evidence for replication in logistic
models of hypomagnesemia (in ARIC and RS only because of
small numbers of subjects with hypomagnesemia in FHS) or linear
models of eGFR (ml/min/1.73 m
2) adjusted for age, sex, and
study center. Results for blood pressure (mm Hg) traits in
association with the SNPs were adjusted for age, age squared,
sex, and BMI to be consistent with the published data from a
GWAS of blood pressure in the CHARGE Consortium, and blood
pressure among treated and untreated individuals was modeled as
described in this publication [24,57]. Inverse-variance weighted
fixed effects meta-analysis was used to determine summary effect
estimates for these additional traits.
We further evaluated these SNPs in association with fasting
glucose and BMD as an in silico lookup in large available datasets
from two consortia. Fasting glucose associations were available
from up to 46,180 subjects of European descent from the MAGIC
Consortium [15], and BMD associations (femoral neck and
lumbar spine) in 19,195 subjects of Northern European descent
from the GEFOS Consortium [16].
To examine the association between serum magnesium levels
and common variation in previously identified magnesium
transporter proteins from model systems [7,28–34] or in genes
with rare variants responsible for monogenic disorders of
magnesium metabolism, we examined associations with SNPs
within 60 kb of the genes [58] and reported the association and
annotation for the lead SNP within each gene region.
Supporting Information
Figure S1 Q-Q plots showing the distribution of observed versus
expected 2log10(p-values) for the meta-analyses of magnesium (A),
sodium (B), and potassium (C) in the CHARGE Consortium.
Found at: doi:10.1371/journal.pgen.1001045.s001 (0.09 MB TIF)
Figure S2 Regional association plots for SNPs and serum
magnesium concentrations in 15,366 white participants from the
CHARGE Consortium. Figures show 2log10(p-values) by chro-
mosomal position around the magnesium-associated regions along
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map within the regions are also noted on the plots. (A) SNPs in
MUC1 region; (B) SNPs in ATP2B1 region; (C) SNPs in DCDC5
region; (D) SNPs in TRPM6 region; (E) SNPs in SHROOM3
region; (F) SNPs in PRMT7 region.
Found at: doi:10.1371/journal.pgen.1001045.s002 (0.17 MB TIF)
Table S1 Study-specific genotyping and imputation information
for discovery and replication studies.
Found at: doi:10.1371/journal.pgen.1001045.s003 (0.04 MB
DOC)
Table S2 SNP associations with serum sodium concentrations at
p,10
-5 in the CHARGE cohorts.
Found at: doi:10.1371/journal.pgen.1001045.s004 (0.06 MB
DOC)
Table S3 SNP associations with serum potassium concentrations
at p,10
-5 in the CHARGE cohorts.
Found at: doi:10.1371/journal.pgen.1001045.s005 (0.03 MB
DOC)
Table S4 Study-specific associations for magnesium levels and
the lead regional magnesium genome-wide association study hits
in the discovery cohorts.
Found at: doi:10.1371/journal.pgen.1001045.s006 (0.05 MB
DOC)
Table S5 SNP association with serum magnesium concentra-
tions at p,10
-6 in the CHARGE cohorts.
Found at: doi:10.1371/journal.pgen.1001045.s007 (0.46 MB
DOC)
Table S6 Study-specific associations for magnesium levels and
the lead regional magnesium genome-wide association study hits
in the replication cohorts.
Found at: doi:10.1371/journal.pgen.1001045.s008 (0.05 MB
DOC)
Table S7 Imputation quality for SNPs with significant and
suggestive association with serum magnesium concentrations.
Found at: doi:10.1371/journal.pgen.1001045.s009 (0.04 MB
DOC)
Table S8 Association betweensystolicanddiastolicblood pressure
with the lead replicated SNPs showing genome-wide significant
associationswith serummagnesiumconcentrationsintheCHARGE
Consortium.
Found at: doi:10.1371/journal.pgen.1001045.s010 (0.04 MB
DOC)
Text S1 Supporting information.
Found at: doi:10.1371/journal.pgen.1001045.s011 (0.10 MB
DOC)
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